The Malaria Vaccine Alliance, known as the MalVax Alliance, is an initiative that emerged from the malaria vaccine R&D community. It brings together representatives from academia, industry, funding agencies, policy and implementation with the simple purpose to share timely knowledge, coordinate efforts, and support progress in malaria vaccine development for the next-generation of malaria vaccines. Our vision is: “Accelerating the development of better vaccines for a malaria free future”.

Malaria vaccine research takes place across many institutions and different geographies, making it difficult to coordinate efforts. MalVax connects these efforts so partners can align priorities, design and share research frameworks, avoid duplicating work, and move faster toward effective vaccines that can have a greater impact on reducing the burden of malaria and save more lives.

Opportunities for malaria vaccine R&D community members to engage with MalVax will take different forms and continue to evolve as the MalVax Alliance takes shape during this first establishment year (2026-27). The three initial technical Working Groups (see Section D in the downloadable FAQs) will create opportunities for engagement with community members. These may include webinars around specific topics, or invitations to feedback on draft outputs as these become available. In February 2027, all community members are invited to the First Global Malaria Vaccine Alliance R&D Conference in Kuala Lumpur (see Section E in the downloadable FAQs) for scientific exchange, interaction with Working Groups, and dialogue to advance next-generation malaria vaccine development.

The goal of the inaugural conference is built around showcasing the most exciting, up-to-date science across the malaria vaccine space. Rather than us second guessing who will have the most exciting results to present, we plan that most talks will be drawn directly from abstract submissions.